Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14541149 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL5170196 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL14671509 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL7983260 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL6578241 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL14541480 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Hydrochloric Acid SCHEMBL4977968 | 0.98 | CSNK1E (0.54) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Hydrochloric Acid SCHEMBL5168479 | 0.98 | CSNK1E (0.54) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Hydrochloric Acid SCHEMBL2232703 | 0.98 | CSNK1E (0.54) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Sulfuric Acid SCHEMBL5172847 | 0.91 | CSNK1E (0.49) | EPHX1CSNK1ESLC15A1ANPEPALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | claimed |
| WO-2013014633-A1 | PROCESS FOR PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-31 | — | — | WO | claimed |
| US-20110178305-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-21 | — | — | US | claimed |
| EP-2288593-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | Ranbaxy Laboratories Limited (IN) | 2011-03-02 | — | — | EP | claimed |
| WO-2009136365-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | WO | claimed |
| EP-3409765-B1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3409765-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | Codexis, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2446025-B1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9404092-B2 | Ketoreductase-mediated stereoselective route to alpha chloroalcohols | CODEXIS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160160187-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-06-09 | — | — | US | disclosed |
| US-9296992-B2 | Ketoreductase-mediated stereoselective route to alpha chloroalcohols | CODEXIS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150240217-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-08-27 | — | — | US | disclosed |
| US-20120190086-A1 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2446025-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | Codexis, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110178305-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-21 | — | — | US | disclosed |
| WO-2011060302-A1 | REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS | AMERICAN PACIFIC CORPORATION (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2288593-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | Ranbaxy Laboratories Limited (IN) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011005527-A2 | KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS | CODEXIS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2009136365-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | WO | disclosed |
| EP-1777213-A1 | Production method of aminochlorohydrin sulfate | Ajinomoto Co., Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178305-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | CYP2S1, TYMS, TBXAS1 | EPHX1 327/4885CSNK1E 1478/4885SLC15A1 2863/4885 |
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | DNPEP, NSUN2, JMJD7 | EPHX1 2820/4885CSNK1E 931/4885SLC15A1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.